Novo Nordisk agreed to acquire Swedish drug-delivery startup Nanexa for up to $1.3 billion, gaining exclusive rights to the company's long-acting injection technology. The deal aims to bolster Novo's portfolio of obesity treatments, building on the success of its GLP-1 drugs like Ozempic and Wegovy. Terms include upfront payments and milestone-based contingencies tied to regulatory and commercial achievements.
Quwwaa is your AI news butler — a personalized brief and assistant for the stories you care about.
See more on Quwwaa — create a free account